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Abstract
Background: Investigating how epigenetic information is transmitted through the mammalian germline is the key
to understanding how this information impacts on health and disease susceptibility in offspring. EED is essential
for regulating the repressive histone modification, histone 3 lysine 27 tri-methylation (H3K27me3) at many
developmental genes.
Results: In this study, we used oocyte-specific Zp3-Cre recombinase (Zp3Cre) to delete Eed specifically in
mouse growing oocytes, permitting the study of EED function in oocytes and the impact of depleting
EED in oocytes on outcomes in offspring. As EED deletion occurred only in growing oocytes and females
were mated to normal wild type males, this model allowed the study of oocyte programming without
confounding factors such as altered in utero environment. Loss of EED from growing oocytes resulted in
a significant overgrowth phenotype that persisted into adult life. Significantly, this involved increased
adiposity (total fat) and bone mineral density in offspring. Similar overgrowth occurs in humans with
Cohen-Gibson (OMIM 617561) and Weaver (OMIM 277590) syndromes, that result from de novo germline
mutations in EED or its co-factor EZH2, respectively. Consistent with a role for EZH2 in human oocytes,
we demonstrate that de novo germline mutations in EZH2 occurred in the maternal germline in some
cases of Weaver syndrome. However, deletion of Ezh2 in mouse oocytes resulted in a distinct phenotype
compared to that resulting from oocyte-specific deletion of Eed.
Conclusions: This study provides novel evidence that altering EED-dependent oocyte programming leads
to compromised offspring growth and development in the next generation.
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Background
Factors regulating oocyte (egg) and sperm programming
and early embryonic development have been associated
with the fetal origins of disease, including reduced cog-
nitive ability and increased chronic diseases, such as
type-2 diabetes, obesity, heart disease and behavioural
anomalies [1–5]. The causes of these defects are poorly
understood, but are likely to be in part due to altered
epigenetic programming of oocytes or sperm that signifi-
cantly impact on embryonic development and underlie
the fetal origin of some of these disorders [1, 2, 4].
Defining how inherited epigenetic information regulates
fetal development and postnatal phenotypic outcomes is
therefore important for understanding how inherited
epigenetic information impacts on human health and
disease. While the establishment of aberrant epigenetic
states has been associated with disease, functional ana-
lyses of epigenetic inheritance that isolate in vivo effects
generated in the germline are not possible in humans.
Here, we have used genetic mouse models to mediate
oocyte-specific deletion of Eed and Ezh2 to understand
how changes in epigenetic information established in the
oocyte can impact on phenotypic outcomes in offspring.
H3K27me3 is a critical epigenetic modification that is
catalysed by polycomb repressive complex 2 (PRC2), a
highly conserved epigenetic modifying complex. PRC2 is
comprised of three core protein subunits: Embryonic
* Correspondence: patrick.western@hudson.org.au
1Centre for Reproductive Health, Hudson Institute of Medical Research and
Department of Molecular and Translational Science, Monash University,
Clayton, Victoria 3168, Australia
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Prokopuk et al. Clinical Epigenetics  (2018) 10:95 
https://doi.org/10.1186/s13148-018-0526-8
Ectoderm Development (EED), Enhancer of Zeste 1/2
(EZH1/2) and Suppressor of Zeste 12 (SUZ12). Global
loss of function to any one of these components results
in drastically compromised enzymatic activity of PRC2,
substantial loss of H3K27me3 and embryonic lethality in
mice [6–8]. Recent studies of germ cells have demon-
strated enrichment of H3K27me3 at key developmental
genes in male and female germ cells [9–11] and the
maintenance of some H3K27me3 marked histones in
mature sperm [12–14]. Furthermore, oocyte-specific de-
letion of Ezh2 results in loss of H3K27me3 in the zygote
and ~ 40% growth restriction in maternal offspring [15].
In humans, de novo germline mutations in EED or
EZH2 lead to Cohen-Gibson (OMIM 617561) or Weaver
(OMIM 28229590) syndromes, which are characterised
by overgrowth, skeletal defects and advanced bone age
[16–23], indicating that PRC2 activity may be required
in the human germline for regulating outcomes in off-
spring. Together, these studies raise the possibility that
PRC2 and H3K27me3 may underpin epigenetic inherit-
ance effects on offspring development and postnatal
outcomes.
During female fetal development, germ cells commit
to oogenesis and enter meiotic prophase [24]. Folliculo-
genesis occurs in early postnatal life and results in estab-
lishment of a finite pool of quiescent primordial follicles
that underpin the female reproductive lifespan. Subse-
quently, primordial follicles are continuously released in
reproductively mature females, initiating a prolonged
period of oocyte growth and maturation that takes
around 21 days in mice and up to 12 months in humans
[25]. While most of this period involves oocyte growth
while in a diploid state, it is completed by rapid matur-
ation of each oocyte through meiosis I and meiosis II,
ultimately producing a haploid oocyte at fertilisation
[26]. Before completion of the first meiotic division, the
diploid oocyte enters the germinal vesicle (GV) stage,
characterised by decondensed chromatin and a period of
high transcription that includes the production of mater-
nal factors (proteins and RNAs) that are required for
directing preimplantation development in the offspring
[27]. In addition to maternal factors, the mature oocyte
carries specific epigenetic information required for off-
spring development, but the nature, extent and effects of
this information on offspring development are not yet
fully understood [28, 29].
Germ cell-specific knockout mouse models have been
valuable for analysing the function of maternal factors in
the absence of confounding effects such as in utero en-
vironment and nutritional influences derived from the
mother [15, 28, 30]. Zp3Cre, is a well-established model
for generating oocyte-specific gene deletion mediated by
transcription of Cre recombinase under control of the
Zona Pellucida 3 (Zp3) promoter [31]. This model
allows the production of offspring from oocytes that lack
specific genes only during their maturation and can be
effectively used for functional analyses of maternal
inheritance [15, 31–33].
Although deletion of the PRC2 component, Ezh2, in
the growing oocyte leads to restricted growth in off-
spring [15], little is known about the role of Eed in the
female germline. However, the PRC1 components, Ring
finger protein 2 (Rnf2) and Ring finger protein 1 (Ring1),
are regulated throughout oogenesis and absence of ma-
ternal RNF2 and RING1 proteins leads to developmental
arrest at the two-cell stage of embryogenesis [30]. More-
over, injection of the H3K27me3-specific demethylase,
Kdm6b, into zygotes resulted in ectopic maternal expres-
sion of specific genes that are normally expressed only
from the paternal allele, demonstrating that maternal
H3K27me3 regulates DNA methylation-independent im-
printing [34]. These data suggest oocyte-specific roles
for polycomb group proteins in the establishment of ma-
ternal factors and/or epigenetic modifications that are
required for correct development of offspring.
In this study, we used Zp3Cre to delete Eed specifically
from growing oocytes. The resulting oocytes lacked
H3K27me3 and produced offspring with significant
overgrowth that involved increased adiposity (percentage
fat) and increased bone mineral density. These data
demonstrate that EED is required in the oocyte for pro-
gramming developmental outcomes that affect life-long
outcomes in offspring. This contrasted with growth re-
striction that resulted from deletion of Ezh2 in growing
oocytes, indicating that while EED mediates epigenetic
inheritance through the maternal germline, the function
of EZH2 is more complex.
Results
Immunofluorescent studies of oocyte development
demonstrated that H3K27me3 is increasingly enriched
in the nucleus of oocytes during follicle growth [35]. In
this study, we used a Zp3Cre transgene to mediate
oocyte-specific deletion of Eed, in order to determine
the effect loss of maternal PRC2 function had on
offspring (Fig. 1a). The Eedfl/fl model was originally de-
veloped by Orkin and colleagues, and results in deletion
of exons 3–6 of Eed and loss of the ability for PRC2 to
catalyse H3K27 methylation [36]. Genotyping of progeny
from Eed floxed females carrying Zp3Cre mated to wild
type males demonstrated that Eed deletion was 100%
efficient in oocytes (Additional file 1: Figure S1; Chi-
square test, nsd). Mouse oocyte growth encompasses
22–24 days, after which they complete meiosis during
maturation within a single day, ultimately producing
haploid ova [37, 38]. Deletion using Zp3Cre occurs early
during oocyte growth, resulting in loss of the target gene
during the majority of the diploid (4C) oocyte growth
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phase [31]. Critically, immunofluorescence demonstrated
that Eeddel/del oocytes contained markedly reduced nuclear
H3K27me3, consistent with substantial loss of PRC2 func-
tion in these cells (Fig. 1b). Initially, we determined
whether deleting Eed in oocytes affected average litter size
produced from Eedwt/wt Eedwt/del and Eeddel/del growing
oocytes. Despite severe depletion of H3K27me3, Eeddel/del
oocytes produced live born pups in normal sex ratios.
However, the average litter size produced by females pro-
ducing Eeddel/del oocytes was significantly reduced com-
pared to females producing Eedwt/wt or Eedwt/del oocytes,
although the causes for the litter size reduction remain
unknown (Fig. 1c, n = 13–20 litters per genotype). This




Fig. 1 Deletion of Eed significantly reduced H3K27me3 in growing oocytes: a Schematic of the study aims—germ cells commit to female development
after E12.5 and new epigenetic information is established in growing oocytes after birth. H3K27me3 is enriched as oocytes grow, with strong enrichment
in the maturing oocyte. Using an Eedfl-Zp3Cre mouse model, we investigated the impacts of deleting Eed in the growing oocyte on offspring weight and
growth. As EED deletion occurs only in growing oocytes, this model allows the study of EED-dependent maternal programming without contributions
from confounding factors such as in utero environment. b Representative confocal images of immunofluorescence in ovary sections from adult Eedfl/fl and
Eedfl/fl;Zp3-Cre female mice producing Eedfl/fl (wild type; wt) and Eeddel/del (homozygous; hom) oocytes, respectively. Merged channels: H3K27me3 (red) and
DAPI (DNA; blue). Eedfl/fl (wt) and Eeddel/del(hom) oocytes are shown within the white dashed line. Images are representative of four biological replicates.
10-μm scale bars. c Average litter sizes from mothers producing Eedfl/fl (wt), Eedwt/del (heterozygous; het) and Eeddel/del (hom) growing oocytes: n= 15, 20
and 13 litters per genotype, respectively, and 7 different mothers per genotype group. ****P< 0.0001. One-way ANOVA plus post hoc Tukey’s multiple
comparisons test. Error bars ± SEM
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offspring derived from oocytes that lack EED and
H3K27me3, specifically during oocyte growth, maturation
and preimplantation development, prior to activation of
the paternal Eed allele.
Mating females with oocyte-specific deletion of Eed to
wild type C57BL/6 males provided the opportunity to
compare isogenic offspring in the absence of confounding
maternal in utero effects (Fig. 2). Importantly, oocytes de-
veloping in Eedwt/fl;Zp3-Cre transgenic mothers have one
intact copy of Eed during the oocyte growth period, when
epigenetic modifications including DNA methylation and
H3K27me3 are established. In contrast, oocytes from
Eedfl/fl;Zp3-Cre transgenic females lack both copies of Eed
(Eeddel/del) and have no EED function in their growing oo-
cytes. Therefore, in this model, we expect the epigenome
of Eeddel haploid oocytes produced by Eedfl/wt;Zp3-Cre fe-
males to be relatively normal as they developed in the
presence of reduced, yet sufficient, EED function during
their growth and maturation. However, Eeddel haploid oo-
cytes produced by Eedfl/fl;Zp3-Cre females lacked EED
protein during oocyte growth and maturation (Fig. 2).
This model allowed the production of heterozygous
(HET) offspring from females producing Eeddel/del (hom)
or Eedwt/del (het) growing oocytes mated to wild type
males. Although HET offspring from Eeddel/del or Eedwt/del
growing oocytes were isogenic, they have two critical dif-
ferences. Firstly, we expect these offspring to be epigeneti-
cally different, reflecting the presence or absence of EED
function in the growing oocyte. Secondly, these offspring
lacked maternal EED during the zygotic to paternal gen-
ome activation phase of preimplantation development.
Therefore, we proposed that differences between the HET
offspring from females producing Eeddel/del or Eedwt/del
growing oocytes could be attributed to altered program-
ming in Eeddel/del growing oocytes and during the earliest
stages of preimplantation development. Similar compari-
sons were made between wild type (WT) offspring from
Eedwt/fl;Zp3-Cre and Eedwt/wt females, which respectively
produced Eedwt/del and Eedwt/wt growing oocytes (Fig. 2).
To identify postnatal differences in offspring due to
compromised EED-dependent programming in the oocyte
and early development, we initially weighed postnatal day
Fig. 2 Schematic of experimental breeding to determine epigenetic differences in isogenic offspring from Eed floxed females: Wild type males
were mated with Eedfl/fl, Eedfl/del;Zp3-Cre and Eedfl/del;Zp3Cre female mice that produce Eeddel or Eedwt haploid oocytes derived from Eedfl/fl (wild
type; wt), Eedwt/del(heterozygous; het) or Eeddel/del (homozygous; hom) growing oocytes. Het oocytes grow and mature in the presence of functional
EED, while hom oocytes grow and mature in the absence of EED function. Production of offspring by mating Eedfl/del;Zp3-Cre and Eedfl/del;Zp3Cre
female mice with isogenic wild type males allowed the comparison of isogenic HET offspring from het and hom oocytes. As the resulting HET
offspring were isogenic and carry identical heterozygous Eed deletion, differences detected could be ascribed to loss of epigenetic regulation by
EED in the oocyte and before cavitation of paternal Eed in the preimplantation embryo. Similar comparisons were made between WT offspring
produced from Eedfl/fl and Eedfl/del;Zp3-Cre females. Comparison of WT and HET offspring produced by Eedfl/fl and Eedfl/del;Zp3-Cre females provides
an internal control identifying the contribution of Eed heterozygosity to the phenotype. Genetically identical offspring are shown in purple dashed box
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(PND) 2 pups generated from Eeddel/del, Eedwt/del and
Eedwt/wt growing oocytes and isogenic wild type sperm
(Figs. 2 and 3a). Remarkably, complete loss of EED specif-
ically in the growing oocyte resulted in a 29% increase in
weight of PND2 HET offspring from Eeddel/del growing
oocytes (average weight 2.19 g, n = 51) compared to PND2
HET offspring from Eedwt/del growing oocytes (average
weight 1.69 g, n = 52) (Fig. 3a P < 0.0001, one-way
ANOVA). In addition, HET offspring from Eeddel/del
growing oocytes had increased nose to rump length, com-
pared to isogenic age-matched HET offspring from Eedwt/
del growing oocytes (Fig. 3b–d). Similarly, HET offspring
from Eeddel/del growing oocytes were significantly longer
and heavier than WT offspring from Eedwt/del growing oo-
cytes, but there was no difference in length or weight be-






Fig. 3 Offspring from Eeddel/del oocytes have increased weight and length that is independent of litter size. a Postnatal day (PND) 2 weights of WT and
HET offspring produced from Eedfl/fl (wt), Eedwt/del (het) and Eeddel/del(hom) oocytes and wild type sperm (WT offspring from wt oocytes n = 118; WT
offspring from het oocytes n = 37; HET offspring from het oocytes n = 52; HET offspring from hom oocytes n = 51). b Representative images showing
two isogenic PND2 male pups. Left: HET offspring from a het growing oocyte; Right: HET offspring from a hom growing oocyte. c Crown to rump
measurements of PND2 male and female pups. d Nose to rump measurements of PND2 male and female pups. c–d WT offspring from wt oocytes n
= 29; WT offspring from het oocytes n = 10; HET offspring from het oocytes n = 10; HET offspring from hom oocytes n = 23) ****P < 0.0001. One-way
ANOVA plus post hoc Tukey’s multiple comparisons test. Data represents mean ± SEM. e Relationship between PND2 weight and litter size: Litter size
vs offspring weight (t33.5 = − 1.32, P = 0.20; variance components: litter ID = 0.0398, residual = 0.0345). Accounting for litter size vs offspring weight: HET
pups from Eeddel/del oocytes were heavier than HET pups produced from Eedwt/del oocytes (t34.8 = 3.44, P = 0.002), WT pups from either
Eedwt/del (t36.3 = 2.81, P = 0.008) and Eed
wt/wt (t33.1 = 2.29, P = 0.03) oocytes
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Eedwt/wt growing oocytes (Fig. 3d). There was no bias in
this PND2 overgrowth phenotype between the sexes
(Additional file 1: Figure S2).
One possible explanation for the increased pup weight
at PND2 was the reduced average litter size observed for
females producing Eeddel/del growing oocytes (Fig. 1c).
To account for this, we analysed the weight data using
linear mixed models to statistically evaluate the litter
size dependent, and litter size independent contributions
to offspring weight. To account for non-independence of
pups from individual litters, we included litter identifica-
tion as a random effect in the analysis. Initially, we en-
sured that there were no differences in offspring weight
due to litter size differences that were attributable indi-
vidual oocyte genotypes. This revealed that the relation-
ship between litter size and offspring weight among WT
and HET pups produced from Eedwt/wt, Eedwt/del and
Eeddel/del oocytes was consistent (litter size by offspring
group interaction: F3,48.4 = 0.048, P = 0.99; variance com-
ponents: litter ID = 0.0423, residual = 0.0346). Next, we
determined the relationship between litter size and
offspring weight for all genotypes. This revealed that as
litter size decreased, there was a minor increase in off-
spring weight (t33.5 = − 1.32, P = 0.20; variance compo-
nents: litter ID = 0.0398, residual = 0.0345; Fig. 3e).
However, this effect was not significant and was insuffi-
cient to account for the substantial increase in the
weight of HET offspring generated from Eeddel/del grow-
ing oocytes compared to HET or WT offspring gener-
ated from Eedwt/del or Eedwt/wt oocytes. In contrast, after
removing the weight change attributable to litter size,
there remained a highly significant increase in weight of
HET pups produced from Eeddel/del growing oocytes
compared to HET pups produced from Eedwt/del oocytes
(t34.8 = 3.44, P = 0.002) and WT pups produced from ei-
ther Eedwt/del (t36.3 = 2.81, P = 0.008) or Eed
wt/wt (t33.1 =
2.29, P = 0.03) growing oocytes (Fig. 3e). Given that this
increase in offspring weight only occurred in the HET
pups generated from Eeddel/del growing oocytes and was
not accounted for by litter size differences, we concluded
that loss of EED in the oocyte and early embryo resulted
in substantial, postnatal overgrowth.
As the Eed HET pups produced were isogenic, the
simplest explanation for this difference is that loss of
maternal EED in the mouse oocyte and zygote led to a
significant early developmental programming effect that
impacted on postnatal weight in offspring from Eeddel/del
compared to Eedwt/del growing oocytes. As EED is
known only to regulate epigenetic outcomes, this post-
natal effect is likely to result from altered epigenetic pro-
gramming in the oocyte and early embryo.
Recent studies in humans have demonstrated that de
novo germline mutations in EED lead to Cohen-Gibson
(OMIM 617561) syndrome, which is characterised by
overgrowth, skeletal defects and advanced bone age [16–
20]. DEXA scanning of the PND2 mouse offspring pro-
duced in this study revealed increased bone mineral
density (BMD) in HET offspring from Eeddel/del growing
oocytes compared to HET controls generated from
Eedwt/del growing oocytes (Eedwt/wt n = 28, Eedwt/del n =
14, Eeddel/del n = 19; P < 0.05, one-way ANOVA; Fig. 4a).
Moreover, fat content was also significantly increased in
PND2 HET offspring from Eeddel/del oocytes compared
to HET offspring from Eedwt/del growing oocytes, and
WT offspring from Eedwt/del and Eedwt/wt oocytes
(Fig. 4b, P < 0.01, one-way ANOVA). Lean muscle con-
tent was significantly reduced in HET offspring from
Eeddel/del growing oocytes, compared to WT offspring
from Eedwt/wt oocytes (Fig. 4c, P < 0.05, one-way
ANOVA), but there was no significant difference be-
tween HET offspring from Eedwt/del and Eeddel/del oo-
cytes. The ponderal index (weight/crown-length3) of
WT and HET offspring from Eedwt/wt and Eedwt/del
growing oocytes, respectively, was not significantly dif-
ferent indicating that there was no substantial effect on
corpulence in these offspring. However, while there was
an unexpected marginal decrease in ponderal index in
WT pups from Eedwt/del growing oocytes compared to
all other treatment groups, the significance of this
change remains unknown (Fig. 4d, *P < 0.05, **P < 0.01
one-way ANOVA).
To determine the weight phenotype observed in PND2
offspring persisted through adult life, female and male
offspring from Eedwt/wt, Eedwt/del and Eed del/del growing
oocytes were weighed at PND30, PND49 and PND130
(Fig. 5a–b, Additional file 1: Figure S2). HET offspring
from Eeddel/del growing oocytes remained significantly
heavier than age-matched WT offspring from Eedwt/wt
oocytes at PND30 (females), PND49 and PND130
(Additional file 1: Figure S2). However, there was no
statistical difference in male weights at PND30, a growth
period encompassing the transition of adolescence to
adulthood in mice. Although the reason for this discrep-
ancy remains unknown, individual variation in growth
and maturation at this time point may explain the
greater individual variability evident in the data. Not-
withstanding this limitation, our findings are consistent
with Cohen-Gibson patients [16], as the weight differ-
ences between animals were partially ameliorated
through time and between sexes such that there was no
longer a consistent statistically significant difference be-
tween HET offspring from Eedwt/del and Eed del/del grow-
ing oocytes at PND30 and at older ages (Fig. 5a–b,
Additional file 1: Figure S2). Calculation of the change in
average sex-specific weights in each group at PND30 and
PND49 relative to PND2, detected no difference in the
growth rates of WT and HET offspring produced from
Eed wt/wt and Eed del/del growing oocytes (Fig. 5c–d).
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In humans, de novo germline mutations in EZH2 lead
to Weaver Syndrome (OMIM 28229590) and de novo
germline mutations in EED lead to Cohen-Gibson syn-
drome, both of which are characterised by overgrowth
[16–18, 21–23]. To determine the germline origin of the
EZH2/EED de novo mutation, comparative SNPs were
analysed in the EZH2 and EED genomic regions in DNA
samples from Weaver syndrome patients and their par-
ents (Fig. 6a). Long range, targeted sequencing revealed
that the causative EZH2 mutations in human patients
occurred either in the maternal or paternal germlines
(Fig. 6b). Although patient numbers are quite restricted
in this study, parent-of-origin appeared to have no effect
on birth weight in human patients Unfortunately, ana-
lysis of two patients carrying EED mutations were unin-
formative, one patient lacked informative SNPs in the
sequenced region and data from the other patient was
inconclusive as amplification of the template failed for
this individual.
An earlier study in mice found that deletion of Ezh2 in
growing oocytes resulted in reduced birth weight in ma-
ternal offspring [15]. As the offspring produced after de-
letion of Eed in growing oocytes resulted in overgrown
offspring, we independently generated offspring from
Ezhfl/fl (Zp3-Cre negative), Ezh2wt/fl;Zp3-Cre and Ezh2fl/
fl;Zp3-Cre mothers. Consistent with deletion of Eed in
growing oocytes, deletion of Ezh2 using the same
Zp3Cre strategy was highly efficient (Additional file 1:
Figure S3) and resulted in substantially reduced
H3K27me3 in growing oocytes. The degree to which
H3K27me3 was lost in Ezh2del/del and Eeddel/del oocytes
was comparable, indicating that loss of EZH2 is unlikely
to be compensated for by the related protein EZH1. In
contrast to Eed, oocyte-specific deletion of Ezh2 resulted
in significantly reduced PND2 weight in HET offspring
from Ezh2del/del growing oocytes compared to WT pups
from Ezh2wt/del and Ezh2wt/wt growing oocytes. However,
there was no difference in PND2 weight between HET
a b
c d
Fig. 4 Offspring from Eeddel/del oocytes have increased bone mineral density and fat content, but reduced lean muscle. a–d Postnatal day (PND)
2: bone mineral density (a), lean muscle content (b), fat content (c), ponderal index (d) in WT and HET offspring produced from Eedfl/fl (wt), Eedwt/
del (het) and Eeddel/del(hom) oocytes and wild type sperm (a–d: WT offspring from wt oocytes n = 28; WT offspring from het oocytes n = 6; HET
offspring from het oocytes n = 8; HET offspring from hom oocytes n = 19). *P < 0.05, **P < 0.01, one-way ANOVA plus post hoc Tukey’s multiple
comparisons test. Error bars ± SEM
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offspring from Ezh2del/del and Ezh2wt/del growing oocytes
(Fig. 7). Significantly, this indicated that deletion of Ezh2 in
growing oocytes resulted in a genetically defined, heterozy-
gous vs wild type reduction in offspring weight, rather than
the epigenetically defined, heterozygous vs heterozygous
difference in offspring weight observed for deletion of Eed
in growing oocytes. A caveat to this is that Ezh2 HET off-
spring from Ezh2wt/del growing oocytes were not signifi-
cantly different in weight to WT offspring from Ezh2wt/del
or Ezh2wt/wt growing oocytes. Therefore, it is likely that
this phenotype results from a combination of genetic and
epigenetic effects mediated through the maternal germline.
Discussion
We have established a model in which oocyte-specific dele-
tion of Eed results in overgrowth in postnatal offspring. Het-
erozygous offspring from Eeddel/del growing oocytes had
increased body weight, length, fat content and bone mineral
density compared to isogenic heterozygous control offspring
from Eedwt/del growing oocytes. Our findings are reminiscent
of weight gains observed in offspring in other epigenetic
models, including mice with disrupted maternal imprinting
of H19 [39]. This is an interesting parallel considering recent
evidence has demonstrated a role for H3K27me3 in DNA
methylation-independent maternal imprinting [34].
Growth trajectories were similar between offspring
from all Eed oocyte genotypes and mice from Eeddel/del
growing oocytes remained moderately larger throughout
adulthood (18 weeks of age), although this overgrowth
phenotype was ameliorated through time. These pheno-
typic effects demonstrate the importance of maternal
PRC2 for establishing fetal growth patterns and provide
evidence that maternal EED regulates offspring growth
and postnatal outcomes. Linear regression analysis indi-
cated that litter size did not strongly correlate with
weight at PND2. Therefore, while litter size may make a
a b
c d
Fig. 5 Offspring from Eeddel/del oocytes have increased weight into adulthood. a–b Postnatal day (PND) 49 weights of female (a) and male (b) WT
and HET offspring produced from Eedfl/fl (wt), Eedwt/del (het) and Eeddel/del(hom) oocytes and wild type sperm (WT offspring from wt oocytes a: n = 43, b
32; WT offspring from het oocytes a n = 9, b n = 10; HET offspring from het oocytes a n = 12, b n = 8; HET offspring from hom oocytes a n = 13, b n =
14). c Average growth trajectories calculated from average weights of female WT and HET offspring at PND2, 30 and 49 (WT offspring from wt oocytes
PND2: n = 14, PND30: n = 14, PND49: n = 14; HET offspring from hom oocytes PND2: n = 10, PND30: n = 10, PND49: n = 10). d Average growth
trajectories calculated from average weights of male WT and HET offspring at PND2, 30 and 49 (WT offspring from wt oocytes PND2: n = 12,
PND30: n = 12, PND49: n = 12; HET offspring from hom oocytes PND2: n = 6, PND30: n = 6, PND49: n = 6). *P < 0.05, ****P < 0.0001; nsd represents no
significant difference. One-way ANOVA plus post hoc Tukey’s multiple comparisons test. Error bars ± SEM
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minor confounding contribution to PND2 offspring size,
the majority of the overgrowth phenotype was attribut-
able to differences in EED-dependent regulation in the
oocyte.
In contrast to the offspring overgrowth observed for
loss of EED in the oocyte, we found that oocytes lacking
EZH2 resulted in reduced offspring birth weight. The
observed EZH2-dependent growth restriction was con-
sistent with a previous study [15]. However, the pattern
of inheritance for EED-mediated effects to offspring was
not consistent with Ezh2 regulating a clear epigenetic in-
heritance effect from the oocyte as HET offspring gener-
ated from Ezh2 wt/del and Ezh2 del/del oocytes were
equivalent, but WT and HET offspring differed in birth
weight. In contrast, loss of Eed in oocytes resulted in
postnatal overgrowth in HET offspring generated from
Eed del/del oocytes compared to HET offspring from Eed
wt/del oocytes. As these offspring were isogenic and de-
rived from oocytes that lacked EED during oocyte
growth and preimplantation development, it appears
that these effects are mediated by altered epigenetic pat-
terning in the oocyte and early life. Furthermore, this
Eed-mediated, inherited phenotype persisted into the
later stages of life (> 18 weeks old). Moreover, while in
the previous study, the EZH2-mediated growth restric-
tion was resolved by 4 weeks of age [15], the increased
offspring size initiated by lack of EED in the oocyte was
more persistent and affected animals through adulthood.
a
b
Fig. 6 De novo missense mutations in EZH2 are maternally or paternally
inherited through the germline in Weaver patients: a PacBio sequencing
was carried out to identify single nucleotide polymorphisms (SNPs) in
DNA from each patient and their respective parental haplotypes.
Informative SNPs (i.e., those that were specific to either parent)
allowed linkage of the patient’s EZH2 mutation in the patient to
either the maternal or paternal allele (example of experimental
pipeline shown). b The EZH2 mutation detected in each patient
is shown in the middle column and parent-of-origin shown on
the right, based on genetic linkage to either the mother or the father
b
a
Fig. 7 Deletion of Ezh2 significantly reduced H3K27me3 in growing
oocytes and weight in offspring: a representative confocal images of
immunofluorescence in ovary sections from adult Ezh2fl/fl and Ezh2fl/
fl;Zp3-Cre female mice. Left panel—merged H3K27me3 (red) and
DAPI (DNA; blue); right panel H3K27me3 shown in greyscale. Oocyte
nuclei are shown within the white dashed line. Images are
representative of three biological replicates; 10 μm scale bars.
b Postnatal day (PND) 2 weights of WT and HET offspring
produced from Ezh2fl/fl (wt), Ezh2wt/del (het) and Ezh2del/del(hom)
oocytes and wild type sperm (WT offspring from wt oocytes n
= 19; WT offspring from het oocytes n = 18; HET offspring from
het oocytes n = 12; HET offspring from hom oocytes n = 19).
*P < 0.05, **P < 0.01, one-way ANOVA plus post hoc Tukey’s
multiple comparisons test. Error bars ± SEM
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Despite the dependence of PRC2 on EZH2 and EED for
catalysing H3K27me3, offspring generated from Eeddel/del
and Ezh2del/del growing oocytes produced remarkably dif-
ferent overgrowth and growth restriction phenotypes in
offspring. Growth restricted offspring were produced from
Ezh2del/del oocytes, but there was no difference in weight
between HET and HET offspring from Ezh2del/wt and
Ezh2del/del oocytes, or between WT and WT offspring from
Ezh2del/wt and Ezh2wt/wt oocytes. However, there was a sig-
nificant difference in weight between genetically different
HET and WT offspring. These observations indicate that
the growth restriction observed in Ezh2 HET vs WT off-
spring is dependent on Ezh2 heterozygosity rather than on
epigenetic or maternal factor differences identified for EED.
One possible explanation is that haploinsufficiency of PRC2
occurs due to compensation for the loss of EZH2 by EZH1
in Ezh2del/del growing oocytes, whereas PRC2 function is en-
tirely lost in Eeddel/del oocytes. However, this scenario seems
unlikely as H3K27me3 levels were similar in Eeddel/del and
Ezh2del/del oocytes, but offspring phenotypes differed sub-
stantially for these two models. Moreover, although growth
restriction was related to Ezh2 heterozygosity in offspring,
Eed heterozygosity did not result in a growth phenotype.
An alternative explanation is that the functions of
EZH2 and EED differ in these models. EED is known to
function only in PRC2 and is essential for PRC2 function
[40]. However, EZH2 can methylate non-histone protein
targets [41–43] and result in phenotypic change that is
PRC2 independent. For example, EZH2 methylates PLZF
in T cells, leading to the ubiquitination of PLZF and its
subsequent degradation [43]. Furthermore, T cell-
specific deletion of Ezh2 did not affect H3K27me3 levels
and induced rapid expansion of natural killer T (NKT)
cells. In contrast, conditional deletion of Suz12 or Eed
halted NKT cell development due to PRC2 destabilisa-
tion [43]. Furthermore, PLZF exerts growth-suppressive
activities [44] and regulates limb-axial skeletal patterning
in mice [45]. Interestingly, skeletal development is com-
promised when Ezh2 is deleted from mesenchymal stem
cells in mice, resulting in reduced skeletal size and reduced
body weight [46]. Therefore, although further analyses are
required to determine the role of Ezh2 in this system,
it remains possible that the growth restriction observed
in Ezh2 heterozygotes derived from Ezh2del/del oocytes
may result from PRC2 independent EZH2 effects in the
embryo rather than reduced H3K27me3 in the oocyte.
Significantly, de novo germline mutations in EED or
EZH2 in humans lead to Cohen-Gibson and Weaver
syndromes, characterised by overgrowth, skeletal defects
and learning/cognitive disabilities [16–18, 21, 22]. As de-
letion of Eed in the maternal germline also resulted in
offspring overgrowth, it appears likely that this mouse
model, at least in part, reflects the developmental defects
typified in Cohen-Gibson syndrome patients. In mice,
this appears to be either an epigenetically inherited
phenomenon, or to result from loss of a maternal factor ac-
tivity of EED, for which the only known activity is to regu-
late epigenetic state through H3K27 methylation. De novo
germline mutations in human EED lead to Cohen-Gibson,
also characterised by fetal overgrowth. Moreover, EED is
very highly conserved between mice and humans and loss
of EED in the oocyte results in similar offspring phenotypes
in both species. Therefore, the EedZP3Cremouse model ap-
pears highly relevant for both the study of maternal epigen-
etic inheritance and Cohen-Gibson syndrome in humans.
An apparent anomaly in the mouse and human
models is that murine offspring produced from oocytes
lacking Ezh2 were born with growth restriction, but pa-
tients with de novo missense mutations in either EZH2
or EED were born with overgrowth [16–18]. The se-
quencing data presented here demonstrated that in two
affected families, de novo p.Pro132Ser (c.394 C>T) and
p.Arg684Cys (c.2050 C>T) changes in EZH2 were ma-
ternally inherited. Both patients presented with in-
creased length at birth (94th and 95th percentiles) and
the patient with the p.Arg684Cys (c.2050 C>T) mutation
was in the 95th percentile for weight and was delivered
preterm. Consistent with the mouse model, which lacks
the EZH2 SET domain and is catalytically inactive [47],
the maternally derived EZH2 mutations in both patients
reduced histone methyltransferase activity, although the
impact of Pro132Ser was less severe than that mediated
by Arg684Cys [23]. The reasons for the differing pheno-
types in mouse and human (i.e., growth restriction in
mouse and overgrowth in Weaver patients) are not clear.
However, mesenchymal stem cell-specific Ezh2 deletion
in mice resulted in large offspring with increased size
and weight in heterozygous animals, but reduced size
and weight in homozygous animals, demonstrating that
partial loss of Ezh2 activity (via heterozygosity of a
loss-of-function mutation) and complete loss of Ezh2
(via deletion) have differing impacts on skeletal size and
birth weight [46]. Whether similar effects of EZH2 dosage
in human patients result in variable skeletal development
remains to be determined. However, human data in
DECIPHER associates copy number variations in either
EZH2 or EED suggesting that both over- and under-growth
can be related to alterations of PRC2 dosage [48].
Epigenetic modifications are established and removed
through the activity of specific chromatin modifying
complexes, which can be altered by mutations, dysregu-
lated transcription, drugs or other environmental influ-
ences. The most prominent examples of epigenetic
dysregulation have been found in cancer, with mutations
in human tumours commonly detected in genes that
regulate chromatin organisation [49]. For example,
gain-of-function mutations in EZH2, EED or SUZ12
occur in multiple cancer types, and both EZH2 and EED
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are current targets for cancer therapy [49]. A prominent
example is provided by Tazemetostat (Epizyme, Inc.), an
EZH1/2 inhibitor in stage I/II clinical trials for treatment
of refractory malignant mesothelioma, lymphomas and a
number of other tumours [50]. Significantly, as observed
in Eed and Ezh2 deleted oocytes, H3K27me3 is substan-
tially and rapidly reduced in growing oocytes of mice
treated with pre-clinical doses of Tazemetostat for just
10 days [51]. While the impacts of maternal Tazemetostat
treatment on offspring outcomes remain unknown, our
study demonstrates that loss of H3K27me3 in growing oo-
cytes substantially affects life-long offspring outcomes.
Importantly, a range of cancers affect men and women
of reproductive age, including tumours carrying gain-
of-function mutations in EZH2. Our mouse model pro-
vides evidence that loss of maternal PRC2 function in
the germline of adult females disrupts H3K27me3 and
results in defects in offspring growth. Based on these
findings, it is likely that drugs targeting PRC2 will alter
the epigenome in the oocytes of patients undergoing
cancer therapy, raising the possibility that these drugs
will affect health outcomes in offspring should the pa-
tient conceive during or soon after treatment [52]. In-
deed, since the oocyte pool in all women is finite, and
oocyte growth and maturation spans 12 months in
humans, these drugs may have effects in patients’ oo-
cytes long after the termination of treatment. Further
evaluation of the impacts of drugs that target PRC2 and
other epigenetic modifier enzymes on oocytes and sperm
is essential to assess the risks of these drugs in repro-
ductive biology. Such studies would reveal the potential
risks of drugs that target epigenetic modifier complexes
and would facilitate development of more informed clin-
ical approaches for patients of reproductive age [52], po-
tentially including germline preservation or avoidance of
pregnancy after treatment has been completed.
Conclusions
Using a genetic approach that deleted Eed specifically in
the growing oocyte, we have demonstrated that this
conserved and developmentally important epigenetic
modifier mediates programming effects in the oocyte
and in the earliest stages of development that are im-
portant for life-long outcomes in mice. Further under-
standing of this and other similar models is essential for
determining how epigenetic modifiers regulate early life
and long-term developmental outcomes in human health
and the developmental origins of disease.
Methods
Mouse strains, animal housing, breeding and ethics
Mice were housed at Monash Medical Centre Animal
Facility using a 12-h light-dark cycle. Food and water
were available ad libitum and room temperature was
21–23 °C with controlled humidity. With the exception
of breeding pairs and newborn mice (up to 3 weeks old),
males and females were weaned at 21 days and kept in
cages of up to five individuals. All animal work was
undertaken in accordance with Monash University Ani-
mal Ethics Committee (AEC) approvals. Zp3Cre mice
(C57BL/6-Tg 93knw/J; Jackson Labs line 003651) were
constructed by Professor Barbara Knowles and obtained
from The Jackson Laboratory. Eed floxed mice (Eedfl/fl)
(B6; 129S1-Eedtm1Sho/J; Jackson Labs line 0022727) were
constructed by Stuart Orkin and colleagues [36] and ob-
tained from the Jackson Laboratory. Ezh2 floxed mice
(Ezh2fl/fl) were constructed by Alexander Tarakhovsy
and colleagues [47]. The Eed and Ezh2 lines were back-
crossed to a pure C57BL6/J and shared with us by Rhys
Allen and Marnie Blewitt, Walter and Eliza Hall Insti-
tute for Medical Research, Melbourne.
Genotyping
Colony maintenance animals were genotyped via tail col-
lection at PND2 or ear punch at weaning by Transnetyx
(Cordova, TN) using real-time PCR assays designed for
each gene (details available on request). Assays were de-
signed based on the genomic structure of Eed and Ezh2
in relation to the conditional genetic modifications
established in [36] and [47], respectively.
Tissue fixation and embedding
Ovaries were fixed in 4% paraformaldehyde (PFA) in PBS
overnight at 4 °C. Samples were then washed in PBS and
left in a 30% sucrose solution overnight at 4 °C. Samples
were then placed in disposable cryostat moulds (Sakura
Finetek, #4565) filled with OCT (Sakura Finetek, #4583)
and frozen in dry ice. Blocks were stored at − 80 °C.
Immunofluorescence
Eight micron sections were cut from OCT embedded
ovaries fixed in 4% PFA, mounted on Superfrost Plus
slides and dried for 5 min before immersing in 1 × PBS.
Sections were then permeabilised by incubation in 1%
Triton × 100 (Sigma, #T8787) in PBS for 10 min at room
temperature (RT). Slides were washed in PBS. Sections
were blocked in PBS containing 5% BSA (Sigma,
#A9647) and 10% donkey serum (Sigma, #D9663) and
incubated for 45 min at RT. Blocking solution was re-
placed by PBS containing 1% BSA and appropriately di-
luted H3K27me3 antibody (1:400, rabbit anti-H3K27me3
Cell Signaling Technologies #C36B11) and incubated for
1 h at RT. Slides were washed three times for 5 min in
PBS and secondary antibodies diluted in 1% BSA in 1 ×
PBS according to antibody dilutions (1:300, donkey
anti-rabbit 594, Alexa Fluor Life Technologies #A21207.
Secondary antibody incubation was carried out in a dark
box for 1 h at RT. Slides were washed three times in
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PBS (5 min each wash) and mounted in ProLong Gold®
containing DAPI (Life Technologies, #P36931) and left
in a dark box overnight to dry. For control slides, only a
secondary antibody was applied. Confocal images were
taken as single optical sections using a Nikon® C1
inverted Confocal microscope. All pictures were taken at
× 80, using a × 40 oil immersion lens.
Phenotypic analysis of offspring
Offspring were weighed at PND2 and/or 30, 49 and 130.
At PND30, 49 and 130, female and male mice were ana-
lysed separately to account for age-related sex-specific
differences. Crown to rump (rump defined by base of
tail) and nose to rump measurements were taken by one
individual to minimise variances in method. Maternal
genotypes were concealed to ensure no bias during
collection of data.
Lunar PIXImus DEXA (bone mineral density, lean muscle,
fat content)
PND2 offspring were measured, euthanised and stored
at − 20 °C. Lunar PIXImus for small animals was used to
measure bone and tissue composition using dual-energy
X-ray absorptiometry (DEXA). Quality control is en-
sured by calibrating Lunar PIXImus to a QC phantom
upon each run. Animal is place inside the region of
interest (ROI), and scan is completed, n = 61. All data
was collected using Lunar Piximus 2.0 software.
Long-range PCR and sequencing of patient and parental
DNA samples
Regions spanning the defined mutations in the EZH2
gene of patients were amplified using long-range PCR in
patient and parental DNA samples and processed for
single molecule real-time (SMRT) sequencing (Pacific
Bioscience) by the Leiden Genome Technology Centre,
Department of Human Genetics, Leiden University
Medical Center, the Netherlands. All samples were
obtained by Professor William Gibson under University
of British Columbia and British Columbia Children’s
Hospital Human Ethics approval numbers H08-00784,
H09-01228 and H10-03215, University of British
Columbia, Vancouver, Canada. Sample preparation and
workflow was carried out as previously described [53].
Primer sequences are included in Additional file 1.
Statistical analysis
One-way ANOVA plus Tukey’s post hoc test was used
to statistically analyse all quantitative data. Pearson r
correlation test used to analyse weight vs. litter size.
PRISM software v6.0e; GraphPad Prism 7 was used to
analyse and graph data sets. Where data are presented
graphically, statistically significant (P < 0.05) post hoc
outcomes are represented by an asterisk.
A linear mixed model with litter ID as a random effect
was used to test for differences among offspring groups
while accounting for the relationship between offspring
weight and litter size. Tests of significance for fixed ef-
fects were undertaken using Satterthwaite approxima-
tion for degrees of freedom and type III sums of squares
for ANOVA. Linear mixed models were implemented in
R v3.3.2 (R Core [54]) using lme4 v1.1-13 and lmerTest
v2.0-33 [55, 56].
Additional file
Additional file 1: Supplementary information. (PDF 389 kb)
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